Company profile: Shasqi
1.1 - Company Overview
Company description
- Provider of a click chemistry-based technology platform (CAPAC) that activates cancer drugs at the tumor site to minimize toxicity and improve outcomes; developer of SQ3370, a clinically validated asset that activates a doxorubicin protodrug with demonstrated safety and efficacy in advanced soft tissue sarcoma; offers antigen-targeting activators and protodrugs for payloads like monoclonal antibodies and traditional chemotherapy agents; in research collaboration with Johnson & Johnson.
Products and services
- CAPAC: A click-chemistry-based platform that activates cancer drugs directly at the tumor site, aiming to minimize toxicity and improve therapeutic outcomes via in-human activation
- Antigen-targeting Activators and Protodrugs: Antigen-targeted components deployed within CAPAC to target and activate cancer drugs at the tumor site using payloads like monoclonal antibodies and traditional chemotherapy agents
- SQ3370: A clinically validated asset that activates a doxorubicin protodrug at the tumor, demonstrating safety and efficacy in patients with advanced soft tissue sarcoma
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Shasqi
NovelStem
HQ: United States
Website
- Description: Provider of diagnostic technology and biotech solutions, including NewStem Diagnostic for early detection of anti-cancer drug resistance aiding targeted cancer treatments, NewStem Therapeutics using proprietary HhESCs for drug and gene screenings to identify genes and drugs for genetic and epigenetic disorders, NewStem Cell Growth Media to improve hPSC growth, and Net Force, a publishing franchise on digital crime, espionage, and crypto.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NovelStem company profile →
Pharmacyclics
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical research and development focused on discovering and developing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Pharmacyclics company profile →
AltruBio
HQ: United States
Website
- Description: Provider of targeted antibody therapeutics for cancer and immune related inflammatory diseases, including ALTB-168, a humanized antibody targeting late-stage, chronically activated T cells with clinical efficacy in psoriasis, psoriatic arthritis, ulcerative colitis, and acute graft versus host disease, and ALTB-268, a second-generation antibody in trials for ulcerative colitis and psoriatic arthritis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full AltruBio company profile →
Origo Biopharma
HQ: Spain
Website
- Description: Provider of research and development of immunotherapeutic products targeting health disorders related to TGF-beta signaling dysfunction, including cancer and fibrosis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Origo Biopharma company profile →
Theriva Biologics
HQ: United States
Website
- Description: Provider of biologics for the prevention and treatment of serious infectious diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Theriva Biologics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Shasqi
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Shasqi
2.2 - Growth funds investing in similar companies to Shasqi
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Shasqi
4.2 - Public trading comparable groups for Shasqi
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →